Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,290 across all filing types
Latest filing 2020-08-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
2020年上半年募集资金存放和实际使用专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2020 年上半年募集资金存放和实际使用专项报告" which translates to "2020 First Half Year Fundraising Funds Deposit and Actual Use Special Report." It details the management, deposit, and usage of funds raised by the company through public offerings and convertible bonds. It references regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange regarding fundraising management. The document includes detailed tables of fundraising amounts, usage, investment projects, and compliance with regulations. It is a specialized report focused on the use and management of raised capital, not a general financial report or earnings release. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2020-08-28 Chinese
2020年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2020 半年度报告摘要' which translates to '2020 Half-Year Report Summary'. It contains detailed financial data for the first half of 2020, including total assets, net profit, revenue, and other financial metrics. It also includes management discussion and analysis of business operations, R&D, and other company activities during the reporting period. The document explicitly states it is a summary of the half-year report and advises investors to read the full report on the official exchange website. The length is 4043 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year with actual financial statements and analysis. It is not a full Annual Report (10-K) or just an announcement (RPA). H1 2020
2020-08-28 Chinese
关于非公开发行股票申请获得中国证监会发行审核委员会审核通过的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the approval of a non-public issuance of A-shares by the China Securities Regulatory Commission's issuance review committee. It is a formal notice about a financing activity (non-public stock issuance) that has been approved but not yet finalized with official written approval. The document is short (397 characters) and focuses on capital raising approval, which aligns with Capital/Financing Update filings. It is not a full financial report or an announcement of voting results, nor is it a regulatory compliance filing or a report publication announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-08-24 Chinese
与招商证券关于《关于请做好郑州安图生物工程股份有限公司非公开申请发审委会议准备工作的函》回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response letter regarding a 2020 non-public stock issuance application by Zhengzhou Antu Bioengineering Co., Ltd. It includes extensive explanations about the use of raised funds, project descriptions, investment budgets, and financial asset details. The content focuses on the company's capital raising activities, specifically a non-public stock issuance, and the allocation and justification of the raised funds. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. Instead, it is a regulatory filing related to capital raising and compliance with the securities regulatory commission's inquiries. The document is lengthy and detailed, but it is not a financial report per se; it is a formal reply to a regulatory body concerning a capital raising application. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-08-21 Chinese
关于非公开发行股票发审委会议准备工作告知函回复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding the preparation work for a non-public issuance of shares and the company's response to a notice from the China Securities Regulatory Commission (CSRC). It discusses regulatory review and approval processes related to a non-public stock issuance. The document does not contain financial statements or detailed financial data but is an update on the company's capital raising process and regulatory compliance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or a certification. Hence, the classification is CAP with high confidence.
2020-08-21 Chinese
关于公司控股股东可交换公司债券解除剩余标的股票担保及信托登记的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the release of stock collateral and trust registration related to the company's exchangeable bonds held by the controlling shareholder. It provides details about the bond issuance, conversion, and the completion of the release of stock guarantees. The document is a formal public announcement about a financing-related event, specifically about bond exchange and collateral release, rather than a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather updates on capital structure and bond-related activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on a specific financing event, confirming this classification with high confidence.
2020-08-18 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.